Endovia Raises $500,000 to Advance CannEpil Veterinary Oncology Program

Endovia Health Sciences has closed an initial $500,000 tranche of a previously announced $1 million financing commitment to advance CannEpil®, its cannabinoid-based pharmaceutical candidate, including an FDA-regulated veterinary programme targeting cancer-related pain in dogs.

The financing, announced September 22, 2026, consists of $500,000 of secured convertible debt from C/M Capital Master Fund, LP. It represents the first tranche of an aggregate $1 million investment commitment linked to Endovia’s CannEpil development and commercialization programme.

The company said the proceeds will support CannEpil development and commercialization, including the U.S. veterinary programme and international commercialization initiatives.

FDA Veterinary Development Programme Already Underway

The financing follows an important regulatory milestone for CannEpil. On August 25, Endovia announced that the FDA Center for Veterinary Medicine established Investigational New Animal Drug (INAD) File No. 14145 for the CannEpil veterinary development programme. The INAD file formally initiated the FDA regulatory process for development of CannEpil as an investigational veterinary pharmaceutical.

Endovia is initially developing CannEpil for management of cancer-related pain in companion animals, beginning with canine oncology.

The company has said it intends to pursue a development pathway involving the FDA’s Minor Use/Minor Species (MUMS) framework and potential Conditional Approval. However, CannEpil remains an investigational product and has not received FDA approval for veterinary use.

CannEpil: A Cannabinoid Pharmaceutical Formulation

CannEpil is described by Endovia as a pharmaceutical-grade cannabinoid formulation containing isolated cannabidiol (CBD) and tetrahydrocannabinol (THC) in an oral liquid formulation manufactured under European Union GMP standards.

The asset was originally developed for human drug-resistant epilepsy and has previously been supplied through certain international access pathways. Endovia subsequently expanded its licensed veterinary field to include oncology and related pain management in dogs, while working with Lupvindol Biosciences on the U.S. veterinary development programme.

Cancer Pain Represents an Unmet Veterinary Need

Pain management is a central component of veterinary oncology, particularly as dogs live longer and cancer becomes an increasingly important clinical condition in ageing companion animals.

Endovia’s rationale is that veterinarians currently use a combination of approved products and off-label approaches to manage cancer-associated pain, with treatment selection influenced by factors including sedation, gastrointestinal or renal effects, controlled-substance requirements and the individual patient’s condition.

CannEpil is therefore being developed not simply as another cannabinoid product, but as a potential regulated pharmaceutical formulation intended for a defined veterinary indication.

That distinction is important. Regulatory approval would require evidence demonstrating appropriate safety, effectiveness, manufacturing quality and product consistency for the proposed use.

$500,000 First Tranche

The September 22 disclosure provides the following financing picture:

The company has not, in the disclosure reviewed, provided all economic details necessary to calculate the eventual equity impact of the convertible instrument. Accordingly, the financing should be described as debt financing rather than an equity raise.

Strategic Significance for Animal Health

The Endovia development sits at the intersection of several emerging areas in companion-animal medicine: Cannabinoid pharmacology + veterinary oncology + pain management + pharmaceutical formulation + regulatory innovation

The more significant point for the animal-health industry is the attempt to move cannabinoid-based products from the broader wellness category toward defined, FDA-regulated veterinary pharmaceutical development.

This could create a materially different commercial model if cannabinoid formulations demonstrate reproducible pharmacology and clinically meaningful benefits in veterinary patients.

What Comes Next?

Opening an INAD file is an important regulatory starting point, but it is not an FDA approval or evidence of clinical efficacy. The programme will need to progress through the development steps established with FDA, potentially including:

• formulation and manufacturing work;

• target-animal safety studies;

• pharmacokinetic evaluation;

• dose selection;

• controlled clinical studies;

• manufacturing and quality requirements;

• regulatory submissions; and

• assessment of eligibility for any applicable MUMS or Conditional Approval pathway.

Endovia has said that Lupvindol is leading scientific development and FDA regulatory activities for the veterinary programme, while Endovia retains ownership of relevant development assets and commercialization responsibilities under its collaboration structure.

Industry Outlook

The CannEpil programme is worth watching because it represents a broader shift occurring in companion-animal therapeutics. Veterinary cannabinoid products have historically occupied a complex space between consumer wellness, nutritional supplements and veterinary medicine.

Endovia is attempting to move one part of that category firmly toward the pharmaceutical pathway: Cannabinoid molecule → defined formulation → FDA INAD → veterinary clinical development → potential regulated therapeutic

Whether that pathway ultimately results in an approved product remains uncertain and will depend on the evidence generated during development.

For AnimalHealthIndia.com, the development is therefore best viewed as a veterinary pharmaceutical and regulatory story rather than a proven cannabinoid-treatment success story.

Bottom Line

Endovia’s $500,000 initial financing tranche gives the company additional capital to advance CannEpil while its veterinary programme moves through the FDA investigational-drug pathway.

The key regulatory milestone is the previously established INAD File No. 14145, which formally opened the FDA-CVM development process for CannEpil’s proposed use in companion-animal oncology.

The programme remains investigational, but it provides another example of how cannabinoid science is increasingly being evaluated through formal veterinary pharmaceutical-development pathways rather than solely through the pet-wellness market.